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associated with visual improvement. The final
visual outcome could have been influenced by
other factors such as the type, duration and
stage of CNV, time of intervention, presence of
macular scarring and retinal atrophy.
Our results are comparable to other recent
studies.4 6 7 Spaide et al.,4 in a series of 266
patients, found visual improvement in a third
at one month. Nearly 6% had worse visual
acuity and 80% of patients had a reduction in
optical coherence tomography measurements
at one month. Rich et al.6 observed improve-
ments in visual acuity and macular thickness
at one week, which continued to month three.
At month three, mean visual acuity had
improved from 20/160 to 20/125 and mean
macular thickness had decreased by 99.6 mm.
We encountered no significant bevacizumab-
related systemic side effects. The only ocular
adverse events included a case of infectious
endophthalmitis in a non-compliant patient
and one retinal pigment epithelial rip. These
patients had poor visual outcome. Other recent
studies also found no serious drug-related
ocular or systemic adverse events.4 6–9
This study was a non-randomized retro-
spective study with short-term follow-up. The
study included a wide range of patients with
various types and stages of CNV, some with
previous treatments. The use of Snellen acuity
measurements also means that direct compar-
ison with previously published data is difficult.
Despite these limitations it clearly demon-
strates the efficacy and short-term safety of
bevacizumab in the treatment of CNV and
confirms the findings of previous studies.
These preliminary results suggest that intravi-
treal bevacizumab is clinically effective in the
management of neovascular AMD. Further
studies are warranted to establish the long-
term safety and efficacy of bevacizumab, and
the optimal dosage for different lesions.
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British family with early-onset
Fuchs’ endothelial corneal
dystrophy associated with
p.L450W mutation in the COL8A2
gene
Endothelial dystrophies produce characteristic
morphological and functional abnormalities of
the cornea. The most prevalent is Fuchs’
endothelial corneal dystrophy (FECD), which is
characterized by bilateral primary cornea guttata
and a reduced endothelial cell density that can
result in corneal oedema, discomfort, and
blurred vision. Histology shows a thickened
Descemet’s membrane with focal posterior
excrescences and endothelial cell loss. The onset
of FECD is typically in the fifth decade of life,1
but an early-onset variant has been described
that shows phenotypic differences from the
more common late-onset disease.2 3 A genome-
wide search of a three-generation family with
early-onset FECD identified a locus on chromo-
some 1p34.3–p32.2 Within this locus a patho-
genic mutation p.Q455K was found in the
COL8A2 gene in this and two additional pedi-
grees.2 Gottsch et al4 recently reported a novel
mutation p.L450W in a separate family with
early-onset FECD.
Case report
A white British family with early-onset FECD
(fig 1) was identified. Patient I:1 (79 years) had
been told he exhibited endothelial pathology
when he was 23 years old. At the age of 75 years
he had a left penetrating keratoplasty with
cataract extraction and intraocular lens implan-
tation. Cornea guttata were present in the right
eye. Patient II:1 (53 years) experienced visual
deterioration in her mid-twenties as a result of
bilateral corneal oedema. A right penetrating
graft was performed at age 34 years and a left
penetrating keratoplasty was performed at age
41 years. Patient II:2 (55 years) was asympto-
matic, but non-contact specular microscopy
showed endothelial pleomorphism and cornea
guttata located both centrally and within the
borders of endothelial cells (fig 2A). Patient III:1
(18 years) was documented to have endothelial
changes at 9 years of age but still has a corrected
acuity of 6/6. Histology of the cornea from
patient I:1 showed thickening of Descemet’s
membrane without cornea guttata (fig 2B).
Using eight primer pairs the coding region of
the COL8A2 gene was sequenced and a previously
reported heterozygous point mutation leading to
p.L450W substitution4 was identified in family
member I:1. The mutation was subsequently
confirmed by direct sequencing in two other
affected family members (fig 1). Individual III:1
has not yet been tested for this change.
Comment
Mutations in the COL8A2 gene account for only
a small proportion (less than 5%)2 of late-onset
FECD, but are associated with early onset
disease.2 4 We describe the phenotype of
early-onset FECD in a white British family,
which is caused by a point mutation (resulting
in p.L450W substitution) in COL8A2. The age of
onset, slit-lamp biomicroscopy findings, and
endothelial imaging are similar to the pheno-
type of a family originally described by
Magovern et al.3 in 1979, in which the
p.L450W change was subsequently reported.4 5
The phenotype, the early age of onset with
endothelial changes detected as early as the
first decade, the presence of apparently intra-
cellular guttae on specular microscopy, and the
absence of excrescences on Descemet’s mem-
brane on histology are the noteworthy clinical
features of the present pedigree. The relation-
ship between the early and late-onset variants
of FECD is, at present, uncertain.6
In conclusion, the identification of the
p.L450W substitution in a second pedigree
suggests that codon 450 in the COL8A2 sequence
might be a mutation hotspot. The possibility also
exists that the two families share a common
ancestor. Unfortunately, no information on other
first-degree relatives of patient I:1 is available.
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Figure 1 Fuchs’ endothelial corneal dystrophy
pedigree and mutation segregation. Affected
patients are shown as filled symbols.
Heterozygous individuals (I:1, II:1 and II:2) carry
the c.1349 T.G transversion mutation resulting
in a p.L450W change in the COL8A2 gene,
which is indicated by an arrow in the
electropherogram. This change was not seen in
the unaffected individual (II:3).
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Three oncocytomas in a short
space of time
Oncocytomas of the caruncle are rare tumours,
found in 3–8% of caruncle excision biopsies.1
They occur most commonly in elderly women.
Clinically, these tumours tend to present as a
slow-growing, asymptomatic mass that is often
tan red in colour.2 Treatment is by complete
surgical excision and recurrence is unusual,
although very rare malignant oncocytomas
occurring in the ocular adnexae have been
reported,3 and there has been a case of
persistent rhinorrhea caused by an oncocytoma
occurring in the lacrimal sac with extension
into the nasolacrimal duct.4
Case reports
A 38-year-old woman presented with a two-
year history of a slowly enlarging cystic lesion
of the left medial canthus, which was causing
increasing irritation. On examination, there
was a smooth, pink, fluid-filled lesion measur-
ing 4 mm in maximum diameter (fig 1). The
cyst was excised under local anaesthesia.
An 81-year-old man with a history of
diabetic retinopathy presented for routine
follow-up and was found to have a cystic
lesion on the left lower eyelid, lying just
proximal to the medial canthus. On examina-
tion, there was a smooth, yellow cystic lesion
that was thought clinically to be a cyst of Moll.
The lesion was excised with no subsequent
recurrence.
An 80-year-old man presented to the clinic
complaining of a lesion affecting the right eye.
On examination, a small cyst was noted
adjacent to the caruncle. Excision was per-
formed and one 7/0 Vicryl suture was put in to
appose the tissue defect, with a provisional
clinical diagnosis of a simple conjunctival cyst.
Comment
All three specimens appeared similar upon
histological examination (fig 2). Each lesion
appeared well circumscribed and was com-
posed of nests and trabeculae of uniform,
polygonal cells with abundant, finely granular
eosinophilic cytoplasm.
The caruncle is a unique anatomical struc-
ture containing elements of both conjunctiva
and skin.5 Oncocytomas (oxyphilic adenomas)
of the caruncle are rare tumours accounting for
only 3–8% of masses of the caruncle.6 These
cases are unusual in that, to our knowledge,
this is the first series in which three cases
presented in the space of eight weeks. This
begs the question: are we misdiagnosing or
indeed underdiagnosing these tumours,
because not all are sent for pathology and
how important or relevant is this?
Oncocytomas are benign neoplasms of onco-
cytic cells, which can occur at a variety of sites.
Ocular adnexal oncocytomas are usually situ-
ated in the lacrimal drainage apparatus of the
caruncle.7 Cases occurring in other sites such as
the eyelid8 have also been documented. The
differential diagnosis should include melano-
cytic melanoma at the top of the list; as this
carries the worst prognosis, melanocytic nae-
vus, benign epithelial tumours, pyogenic gran-
ulomas and haemangiomas, along with several
other rarer lesions.9
As already mentioned, oncocytomas are by
and large benign in nature and usually only
require excision for cosmetic purposes or if
they cause irritation to the patient. They do,
however, have a real potential to recur in cases
of incomplete excision10 and can be locally
aggressive and occasionally turn malignant.
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Figure 2 Morphological structure of early-onset Fuchs’ endothelial corneal dystrophy corneas (A)
specular endothelial microscopy of individual II:2. There is cellular pleomorphism and multiple non-
reflecting areas. (B) Histology of cornea of individual I:1. There is a thickened Descemet’s membrane
but without posterior excrescences.
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Figure 1 Smooth, fluid-filled lesion of medial
canthus. Informed consent was obtained for
publication of this figure.
Figure 2 Tumour composed of bland cells with
abundant granular, eosinophilic cytoplasm
(haematoxylin and eosin, original magnification
6200).
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